Pacific Therapeutics (PCFTF) 0.1171 $PCFTF
CSE: 2016-0307 - Consolidation - Pacific Therapeutics Ltd. (PT)
Marketwired - Thu Mar 10, 2:17PM CST
Pacific Therapeutics Ltd. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post consolidation share for each thirty (30) pre consolidation common shares. No fractional shares will be issued. Any fraction of a share will be rounded down to the nearest whole number.
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.51 (-0.02), GALT: 1.55 (+0.05), LLY: 81.98 (+0.39), BMY: 75.56 (-0.12), GLPG: 53.01 (+0.11), GILD: 88.55 (+2.00), IBIO: 0.63 (-0.01), TEVA: 54.33 (-0.40), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 75.56 (-0.12), GLPG: 53.01 (+0.11), GILD: 88.55 (+2.00), CGEN: 6.56 (-0.03), IBIO: 0.63 (-0.01), TEVA: 54.33 (-0.40), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02)
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.64 (+0.07), APRI: 0.36 (+0.03), ACOR: 26.05 (+0.45)
Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 88.55 (+2.00), CNAT: 2.28 (+0.08), GALT: 1.55 (+0.05)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 287.35 (-0.43), ASPX: 100.96 (unch), BMY: 75.56 (-0.12), GSK: 44.04 (+0.16), GILD: 88.55 (+2.00), CGEN: 6.56 (-0.03), IBIO: 0.63 (-0.01), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02), FPRX: 47.90 (+0.54)
Pacific Therapeutics Ltd. Announces United States Issuance of Patent for Treating Fibrosis
TheNewswire.ca - Mon Jun 01, 7:37AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
IIROC Trade Resumption - PT
CNW Group - Tue May 19, 1:50PM CDT
Trading resumes in:
Pacific Therapeutics Signs LOI to Sell Fibrosis and Erectile Dysfunction Therapeutics Technologies
ACCESSWIRE - Tue May 19, 1:31PM CDT
VANCOUVER, BC / ACCESSWIRE / May 19, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
IIROC Trading Halt - PT
CNW Group - Tue May 19, 1:22PM CDT
The following issues have been halted by IIROC:
Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pacific Therapeutics Ltd. Announces Change Of Auditor
TheNewswire.ca - Wed Apr 22, 7:14PM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
TheNewswire.ca - Fri Apr 10, 7:30AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company" is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities.
CSE: 2016-0307 - Consolidation - Pacific Therapeutics Ltd. (PT)
Marketwired - Thu Mar 10, 2:17PM CST
Pacific Therapeutics Ltd. has announced a consolidation of its issued and outstanding share capital on the basis of one (1) post consolidation share for each thirty (30) pre consolidation common shares. No fractional shares will be issued. Any fraction of a share will be rounded down to the nearest whole number.
Pulmonary Fibrosis - Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/76pwpp/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Pulmonary Fibrosis - Overview - Pipeline Products for Pulmonary Fibrosis - Comparative Analysis - Pulmonary Fibrosis - Therapeutics under Development by Companies - Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Pulmonary Fibrosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pulmonary Fibrosis - Products under Development by Companies - Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Advinus Therapeutics Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Angion Biomedica Corp. - aTyr Pharma, Inc. - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Digna Biotech, S.L. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - HanAll Biopharma Co., Ltd. - HEC Pharm Co., Ltd. - Histocell S.L. - iBio, Inc. - IMMD Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - NicOx S.A. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/76pwpp/pulmonary
PSTI: 1.51 (-0.02), GALT: 1.55 (+0.05), LLY: 81.98 (+0.39), BMY: 75.56 (-0.12), GLPG: 53.01 (+0.11), GILD: 88.55 (+2.00), IBIO: 0.63 (-0.01), TEVA: 54.33 (-0.40), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02)
Global Idiopathic Pulmonary Fibrosis Therapeutics Pipeline Review 2015
M2 - Wed Jan 06, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/63sldq/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - List of Tables - List of Figures - Introduction - Idiopathic Pulmonary Fibrosis Overview - Therapeutics Development - Pipeline Products for Idiopathic Pulmonary Fibrosis - Overview - Pipeline Products for Idiopathic Pulmonary Fibrosis - Comparative Analysis - Idiopathic Pulmonary Fibrosis - Therapeutics under Development by Companies - Idiopathic Pulmonary Fibrosis - Therapeutics under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Pipeline Products Glance - Clinical Stage Products - Early Stage Products - Unknown Stage Products - Idiopathic Pulmonary Fibrosis - Products under Development by Companies - Idiopathic Pulmonary Fibrosis - Products under Investigation by Universities/Institutes - Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - Afferent Pharmaceuticals, Inc. - AnaMar AB - Biogen, Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Galapagos NV - GenKyoTex S.A. - Gilead Sciences, Inc. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Isarna Therapeutics GmbH - MedImmune, LLC - Moerae Matrix, Inc. - MorphoSys AG - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. - Respira Therapeutics, Inc. - Rhizen Pharmaceuticals SA - Ribomic Inc. - Sanofi - Teva Pharmaceutical Industries Limited - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/63sldq/idiopathic
BMY: 75.56 (-0.12), GLPG: 53.01 (+0.11), GILD: 88.55 (+2.00), CGEN: 6.56 (-0.03), IBIO: 0.63 (-0.01), TEVA: 54.33 (-0.40), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02)
Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.64 (+0.07), APRI: 0.36 (+0.03), ACOR: 26.05 (+0.45)
Liver Cirrhosis Pipeline Review, H1 2015 - 12 Key Comapnies
M2 - Thu Jun 11, 9:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2ctvbp/liver_cirrhosis) has announced the addition of the "Liver Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alfa Wassermann S.p.A - Conatus Pharmaceuticals Inc. - Digna Biotech, S.L. - Galectin Therapeutics, Inc. - Gilead Sciences, Inc. - GNI Group Ltd. - Pacific Therapeutics Ltd. - PharmaIN Corporation - Pharmicell Co., Ltd. - S-Evans Biosciences, Inc. - Stelic Institute & Co. - Stempeutics Research Private Limited For more information visit http://www.researchandmarkets.com/research/2c..._cirrhosis
GILD: 88.55 (+2.00), CNAT: 2.28 (+0.08), GALT: 1.55 (+0.05)
Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015
M2 - Tue Jun 02, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cp3333/idiopathic) has announced the addition of the "Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Pulmonary Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Pulmonary Fibrosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AdAlta Pty Ltd. - Aeolus Pharmaceuticals, Inc. - AnaptysBio, Inc. - Auspex Pharmaceuticals, Inc. - Biogen Idec Inc. - Bioneer Corporation - BiOrion Technologies B.V. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Carolus Therapeutics, Inc. - Celgene Corporation - Chong Kun Dang Pharmaceutical Corp. - Compugen Ltd. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - Five Prime Therapeutics, Inc. - GenKyoTex S.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - HanAll Biopharma Co., Ltd. - Histocell S.L. - iBio, Inc. - ImmuneWorks, LLC - Inventiva SAS - Kadmon Corporation, LLC - Kasiak Research Pvt. Ltd. - Kyorin Pharmaceutical Co., Ltd. - Lanthio Pharma B.V. - LTT Bio-Pharma Co., Ltd. - MedImmune, LLC - Moerae Matrix, Inc. - MSM Protein Technologies, Inc. - Pacific Therapeutics Ltd. - Pharmaxis Limited - Progenra, Inc. For more information visit http://www.researchandmarkets.com/research/cp3333/idiopathic
BIIB: 287.35 (-0.43), ASPX: 100.96 (unch), BMY: 75.56 (-0.12), GSK: 44.04 (+0.16), GILD: 88.55 (+2.00), CGEN: 6.56 (-0.03), IBIO: 0.63 (-0.01), FGEN: 17.86 (unch), CELGZ: 1.21 (-0.02), FPRX: 47.90 (+0.54)
Pacific Therapeutics Ltd. Announces United States Issuance of Patent for Treating Fibrosis
TheNewswire.ca - Mon Jun 01, 7:37AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
IIROC Trade Resumption - PT
CNW Group - Tue May 19, 1:50PM CDT
Trading resumes in:
Pacific Therapeutics Signs LOI to Sell Fibrosis and Erectile Dysfunction Therapeutics Technologies
ACCESSWIRE - Tue May 19, 1:31PM CDT
VANCOUVER, BC / ACCESSWIRE / May 19, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. IIROC Trading Halt - PT
CNW Group - Tue May 19, 1:22PM CDT
The following issues have been halted by IIROC:
Pacific Therapeutics Announces Extension of Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Tue Apr 28, 3:20PM CDT
VANCOUVER, BC / ACCESSWIRE / April 28, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pacific Therapeutics Ltd. Announces Change Of Auditor
TheNewswire.ca - Wed Apr 22, 7:14PM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
Pacific Therapeutics Ltd. Announces United States Allowance of Patent for Treating Fibrosis
TheNewswire.ca - Fri Apr 10, 7:30AM CDT
(via Thenewswire.ca)
PT: 0.66 (-0.03)
Pacific Therapeutics Announces Temporary Re-Pricing of Outstanding Warrants
ACCESSWIRE - Wed Apr 01, 6:15PM CDT
VANCOUVER, BC / ACCESSWIRE / April 1, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (PINKSHEETS: PCFTF) (Frankfurt: 1P3) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. Pacific Therapeutics Announces Closing of Non-Brokered Financing
ACCESSWIRE - Mon Mar 23, 7:40AM CDT
VANCOUVER, BC / ACCESSWIRE / March 23, 2015 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (1P3.F) (the "Company"
is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulation of existing FDA approved drugs for large markets. The Company's lead programs focus on diseases of excessive scarring (fibrosis) and erectile dysfunction (ED) which are $1 billion plus market opportunities. 
